Requires NJ FamilyCare to reimburse inpatient providers for long-acting injectable antipsychotic drugs at outpatient reimbursement rate.

This bill requires New Jersey's Medicaid program (NJ FamilyCare) to pay inpatient hospitals the same rate for long-acting injectable antipsychotic drugs as it does for outpatient use. It directly affects hospitals and inpatient providers who treat patients with serious mental illnesses like schizophrenia or bipolar disorder. The key mechanism mandates that reimbursement for these drugs in hospitals must be separate from standard hospital payment systems (DRGs) and match the outpatient rate, which reflects the actual drug cost. This change aims to ensure hospitals receive adequate reimbursement for these high-cost medications, which are designed to manage symptoms for up to 24 weeks with a single dose.